Multi-million pound award aims to create new breakthrough therapies

A recently-formed health consortium, jointly led by the National Institute for Health Research Birmingham Biomedical Research Centre (NIHR Birmingham BRC) and NHS Wales, has been awarded £7 million by Innovate UK to ensure more patients benefit from a new generation of breakthrough therapies.
The Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC) will operate from four centres: University Hospitals Birmingham NHS Foundation Trust (UHB), Cardiff and Vale University Health Board, Abertawe Bro Morgannwg University Health Board and Nottingham University Hospital.
The Midlands-Wales collaborative is one of only three centres in Britain awarded funding from the Industrial Strategy Challenge Fund by Innovate UK, the government’s innovation agency, to develop an advanced therapy treatment centre.
The NIHR Birmingham BRC is a partnership between University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, and has a long-standing track record in cell therapy innovation and translation. NHS Wales will be joint lead for this centre though the Welsh Blood Service, Velindre NHS Trust.
Its vision is to enable UK Advanced Therapy Medicinal Product (ATMP) companies to reach the clinical market while building clinical capacity across the UK to benefit patient outcomes.
ATMPs, which can be cell or gene therapies, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers.
Read the full article here.